News >

Halmos Highlights Advances in Squamous NSCLC

Caroline Seymour
Published: Tuesday, Nov 06, 2018

Emmanuel S. Antonarakis, MD

Balazs Halmos, MD, MS
The addition of pembrolizumab (Keytruda) to chemotherapy should define the frontline standard of care for patients with metastatic squamous non–small cell lung cancer (NSCLC), following the results of the phase III KEYNOTE-407 trial, said Balazs Halmos, MD.

on Advanced Non–Small Cell Lung Cancer, Halmos discussed the latest developments in the treatment paradigm for patients with squamous cell NSCLC.

OncLive: How have recent clinical trials altered the management of squamous NSCLC?

Halmos: At the meeting, I covered major advances in the management of advanced squamous cell lung cancer. This certainly has been a breakthrough year in progress for this particular subset of patients. Up until a few years ago, the standard of care had remained doublet chemotherapy for frontline management of squamous cell lung cancer. The major thing that we learned was what not to use, such as bevacizumab (Avastin) or pemetrexed.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication